T cells become dysfunctional when they encounter self antigens or are exposed to chronic infection or to the tumour microenvironment 1 . The function of T cells is tightly regulated by a combinational co-stimulatory signal, and dominance of negative co-stimulation results in T cell dysfunction 2 . However, the molecular mechanisms that underlie this dysfunction remain unclear. Here, using an in vitro T cell tolerance induction system in mice, we characterize genome-wide epigenetic and gene expression features in tolerant T cells, and show that they are distinct from effector and regulatory T cells. Notably, the transcription factor NR4A1 is stably expressed at high levels in tolerant T cells. Overexpression of NR4A1 inhibits effector T cell differentiation, whereas deletion of NR4A1 overcomes T cell tolerance and exaggerates effector function, as well as enhancing immunity against tumour and chronic virus. Mechanistically, NR4A1 is preferentially recruited to binding sites of the transcription factor AP-1, where it represses effectorgene expression by inhibiting AP-1 function. NR4A1 binding also promotes acetylation of histone 3 at lysine 27 (H3K27ac), leading to activation of tolerance-related genes. This study thus identifies NR4A1 as a key general regulator in the induction of T cell dysfunction, and a potential target for tumour immunotherapy.
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T cell tolerance maintains T cell unresponsiveness to self tissues to avoid autoimmune diseases. Activation versus tolerance of T cells is determined by a combinational signal consisting of both positive co-stimulation and negative co-inhibition [2] [3] [4] . Dominant co-inhibitory signals induce T cell tolerance 1, 5 . Moreover, higher expression of co-inhibitory receptors, including PD-1, programmes CD8 + T cells to become dysfunctional or exhausted in cancer or chronic viral infection 1, 5 . However, the epigenetic and transcriptional regulation that underlies T cell dysfunction remains elusive.
To address this, we generated tolerant T (T tol ) cells from mice using our previously reported in vitro system 2 , and carried out a genomewide transcriptomic and epigenetic assessment on these cells (Fig. 1a) . Gene expression analysis revealed that T tol cells were distinct from other T cell subpopulations including in vitro-differentiated helper T (T H 1, T H 2 and T H 17), natural regulatory T (nT reg ) (also known as thymus-derived T; nT reg ) and naive T cells (Extended Data Fig. 1a-c) . A total of 2,357 genes were uniquely expressed in T tol cells (Fig. 1b and Supplementary Table 1 )-a change of twofold in comparison with T H 1, T H 2 and T H 17 cell subpopulations. Specifically, anergy-related genes (Cblb, Dgka, Rnf149, Tagap1 and Nfatc1) and transcriptional repressors (Rel, Foxp1 and Tgif1) were greatly upregulated in T tol cells, whereas the expression of effectors (Il2, Ifng, Gzmb, Il17a and Il21) and translational components (ribosomal genes such as Rps29, Rpl35, Rpl14, Rplp2 and Rpl26) were substantially decreased (Fig. 1b) , indicating a quiescent state in these cells. Ingenuity pathway analysis (IPA) displayed a close association of T cell tolerance with abnormal T cell differentiation, as well as with the IL-2/STAT5 signalling axis and with NR4A1-regulated transcriptional changes (Extended Data Fig. 1d ). When we compared the T tol transcriptome with other dysfunctional T cell types including chronic virus-induced exhausted CD4
+ T (T exh ) cells (1,626 differentially expressed genes in T exh cells compared with effector T cells) and NF-AT1-overexpressed anergic CD4
+ T (T NF-AT ) cells (1,106 differentially expressed genes in T NF-AT compared with the control group) 6, 7 , we found that 174 genes were shared among these three T cell populations (Extended Data Fig. 1e , and Supplementary Tables 1 and 2 ). Notably, genes associated with the dysregulation of the T cell receptor (TCR) and JAK-STAT signalling pathways showed the greatest overlap among T tol , T exh and T NF-AT cells, whereas genes involved in ribosome-, proteasome-, and spliceosome-related pathways were altered to a larger extent in T tol cells (Fig. 1c) .
We next examined the histone modification status in T tol cells (Extended Data Fig. 2a) . Trimethylation of Lys4 on histone 3 (H3K4me3), which is a marker of actively transcribed genes, showed clear differences between T tol cells and other T cell subsets including T H 1, T H 2, T H 17, nT reg , induced regulatory T (iT reg ) and naive T cells. Only 25% of H3K4me3 islands were located near transcription start sites (TSSs) in T tol cells, compared with 53-65% in other T cell subsets 8 ( Fig. 1d and Extended Data Fig. 2a ). These findings are consistent with a recent observation that chromatin accessibility was reduced at TSS regions in T exh cells 9 . By contrast, H3K27me3 occupancy at TSSs was negligibly altered among T cell subsets (Extended Data Fig. 2b, c) . We further quantified H3K4me3 and H3K27me3 modifications for each gene, and revealed that the percentage of genes associated with dual modifications of H3K4me3 and H3K27me3 was higher in T tol cells than in other T cell types (Extended Data Fig. 2d ). Visualization of gene loci showed that in T tol cells, lineage-specific effectors (Ifng, Il4 and Il17a) and transcription factors (Tbx21, Gata3 and Rorc) were marked by low levels or absence of H3K4me3 and H3K27me3-consistent with their transcriptional silence. Conversely, anergy-associated genes (Egr3, Dgkz and Cdkn2a), as well as exhaustion-related genes (Lag3, Pdcd1 and Tigit), displayed higher levels of H3K4me3 (Extended Data Fig. 2e -g and Supplementary Table 1 ) [10] [11] [12] [13] [14] , verifying that the signatures of T cell tolerance, anergy and exhaustion share common features 15 . Notably, Tagap1, Clec2i and Nr4a1, which were identified as tolerance-related genes based on their transcript levels in T tol cells, showed increased H3K4me3 signals (Fig. 1e and Supplementary Table 1) . Integration of our epigenetic and transcriptome data showed that 112 genes were upregulated and marked with overall permissive histone modifications in T tol cells, whereas 228 genes were downregulated and displayed repressive histone modifications (Supplementary Table 3 ). Seven modules were categorized (Extended Data Fig. 2h ). Ribosome-, mitochondria-and proteasome-related genes were suppressed in T tol cells, and changes in the expression of genes encoding transcription Letter reSeArCH factors or proteins involved in the ubiquitination pathway (upregulation, Nr4a1 and Gatad2b; downregulation, AP-1 subunits Junb and Jund) were also observed (Extended Data Fig. 2h) . Collectively, these results show that CD4 + tolerant T cells display distinct gene expression and epigenetic changes compared with other T cell types.
Our transcriptome analysis above identified specific upregulation of the transcription factor NR4A1 in T tol cells. To investigate this further, we examined NR4A1 expression in in vivo-generated T tol cells 16 ( Fig. 2a-c and Extended Data Fig. 3a-c) . We observed a transcriptional reduction of Il2, Ifng and Tbx21, and an increase in Cblb and Itch mRNA expression, confirming the upregulation of NR4A1. In contrast with activated and naive T cells, a substantial amount of NR4A1 was stably expressed in T tol cells after restimulation either with anti-CD3 antibody or with antigen-presenting cells (APCs) loaded with chicken ovalbumin (OVA) residues 323-339 (OT-II peptide) (Fig. 2b, c and Extended Data Fig. 3a) . We next overexpressed NR4A1 in CD4 + T cells and found that Il2, Ifng, Tbx21 and Hivep3 (which is a coactivator for IL-2 production) 17 were strongly suppressed, whereas the expression of anergy-related genes Cblb, Itch and Klf4 was increased, compared with control vector-transduced T cells (Extended Data Fig. 3d) . Under T H cell polarizing conditions, enforced NR4A1 expression severely impaired both T H 1 and T H 17 cell differentiation, but no appreciable changes were observed in iT reg and T H 2 cells (Extended Data Fig. 3e ). In addition, overexpression of NR4A1 inhibited IFNγ expression in CD8 + T cells (data not shown). Furthermore, a loss-of-function assessment showed that ablation of NR4A1 resulted in a considerable enhancement of IL-2 and/or IFNγ production in both CD4
+ and CD8 + T cells ( Fig. 2d and Extended Data Fig. 4a, b) , as well an increase in cell expansion (data not shown).
We then examined whether NR4A1 is required for the induction of T cell tolerance in vivo. In an oral tolerance or a peptide-induced tolerance model 16, 18 , NR4A1 deficiency blocked the formation of T cell tolerance, and enhanced the production of IL-2 and IFNγ (Extended Data Fig. 4c, Fig. 2e, f) . By contrast, no appreciable change was evident in Foxp3 + T reg populations ( Fig. 2e and data not shown) . These results suggested a conventional T cell-intrinsic function of NR4A1 in T cell tolerance. We also generated chimeric mice reconstituted 
Letter reSeArCH with wild-type and Nr4a1
−/− bone marrow cells, which demonstrated that NR4A1 deficiency did not affect T reg cell development or homeostasis (Extended Data Fig. 4d )-consistent with previous work that found that NR4A1 was dispensable in the control of these processes 19 . Furthermore, we investigated whether NR4A1 is involved in T cellmediated colitis, by transferring Nr4a1
mice. Mice transduced with Nr4a1 −/− T cells exhibited more severe weight loss and colon inflammation than those with wild-type cells, and twice as many IL-17A-and IFNγ-producing T cells were detected in colon lamina propria from Nr4a1 −/− T cell-bearing mice (Fig. 2g , h and Extended Fig. 5a-d) . Altogether, our findings indicate that NR4A1 controls T cell tolerance.
Previous studies showing the upregulation of NR4A1 in chronic virus-associated T cell exhaustion 20, 21 led us to investigate the role of NR4A1 in tumour-specific CD8 + T cells. In mice with OVA-expressing EL4 cells (E.G7 lymphoma), treatment via PD-1 blockade not only led to tumour shrinkage (data not shown), but also substantially reduced Nr4a1 mRNA expression in tumour-infiltrating OVA-specific CD8 + T cells compared with the control group (Fig. 3a) . Open chromatin region analysis of these cells revealed that the NR4A1-binding motif was significantly reduced after anti-PD1 treatment, whereas binding motifs for BATF, IRF1 and ETS-RUNX were significantly enriched (Fig. 3b ). These data, together with previous work on PD-L1 blockade in chronic viral infection 20 , support the hypothesis that NR4A1 is linked to CD8 + T cell dysfunction. Adoptive transfer of Nr4a1 −/− transgenic CD8 + T recognizing OVA 257-264 peptide (OT-I) cells into E.G7 tumour cell-bearing mice nearly eliminated tumours, in contrast with wild-type OT-I cells and a PBS control group (Fig. 3c, d ). Six days after T cell transfer, two to three times as many tumour-infiltrating Nr4a1 −/− OT-I cells were recovered than cells of the wild-type OT-I group. Although wild-type and Nr4a1 −/− T cells did not show much difference in their expression of IFNγ and TNF (also known as TNFα), surface PD-1 and TIM-3 expression were significantly decreased in the absence of NR4A1 (Extended Data Fig. 6a-c) . Moreover, we extended the tumour model to 25 days in a new transfer assay (Extended Data Fig. 6d ). Tumour sizes in mice receiving Nr4a1 −/− OT-I were significantly smaller than the wild-type control group (Extended Data Fig. 6e ). Approximately twice as many Nr4a1 −/− than wild-type OT-I cells were recovered from tumours and PD-1 and TIM-3 expression levels in donor T cells were significantly reduced, whereas BCL2 expression was notably increased (Extended Data Fig. 6f, g ). By contrast, IFNγ, TNF and CD107A expression levels were appreciably higher in Nr4a1 −/− than in wild-type OT-I cells (Extended Data Fig. 6h, i) .
In the context of acute viral infection (lymphocytic choriomeningitis virus (LCMV); Armstrong strain), Nr4a1 ablation in P14 T cells increased CD8
+ T cell proliferation and T-bet expression, but had no effect on KLRG1 lo CD127 hi CD8
+ memory precursor cell formation, when compared with the Nr4a1 +/− control group (Extended Data Fig. 7a-c) . We then looked at chronic viral infection (LCMV, clone 13 strain) in chimeric mice reconstituted with Nr4a1 −/− and wild-type bone marrow cells. Four weeks after viral infection, higher percentages of both GP33
+ and GP33 − Nr4a1-deficient CD8 + T cells in spleens were observed compared with wild-type cells, and Nr4a1-deficient CD8 + T cells were marked with lower PD-1 and TIM-3 expression than wild-type cells (Fig. 3e) . IFNγ, CD107A and Ki-67 expression were significantly enhanced in GP33
+ Nr4a1 −/− T cells compared with wild-type cells (Fig. 3f and Extended Data Fig. 7d, e) . Similar patterns were also observed in peripheral lymph nodes, blood, lung and liver (data not shown). Collectively, our data show that NR4A1 deficiency can prevent CD8 + T cell dysfunction. Microarray analysis showed that 2,504 genes altered their expression in CD4
+ T cells that overexpressed NR4A1 compared with mock-transduced cells (Extended Data Fig. 8a ). Among NR4A1-regulated genes, 290 (of which 178 were downregulated and 112 upregulated) overlapped with genes associated with T tol cell generation (Extended Data Fig. 8a and Supplementary Table 4) . Notably, a core cluster of genes that are critical for T cell activation or dysfunction were similarly regulated in both Nr4a1-overexpressing T cells and T tol cells, including Il2, Ifng, Il21, Gzmb, Stat1, Batf, Jund, Dgka, Hivep3 17 , Nt5e (encoding CD73) 22 , Cd96 (also known as Tactile) 23 , Gata3 24 and Cdkn1b (Fig. 4a  and Supplementary Table 4) .
Next, we conducted a chromatin-immunoprecipitation followed by sequencing (ChIP-seq) assessment on NR4A1 to define its target. Global mapping analysis showed that most of the 50 million short reads were enriched at intergenic regions, exons and introns, and 14,723 gene loci were bound by NR4A1 (Extended Data Fig. 8b-d , and Supplementary Table 5 ). We then compared NR4A1-occupied genes with those that were differentially expressed in T tol cells and/or T cells that overexpressed NR4A1, and found that around 70% of T tol genes were bound by NR4A1 (Extended Data Fig. 8d) . Analysis of NR4A1-binding sites unexpectedly revealed that the top NR4A1-binding Tumour weight (g) P = 0.0061 P = 0.028 Letter reSeArCH motifs were AP-1-containing consensus sequences and canonical NR4A1-binding sequences (Extended Data Fig. 8e) . To validate this, we performed anti-c-Jun (c-Jun is a subunit of AP-1) ChIP-seq assays in activated T cells, and found that a substantial number of NR4A1-binding sites overlapped with c-Jun sites (Fig. 4b and Extended Data Fig. 8f) .
As NR4A1 bound predominantly at non-promoter regions (Extended Data Fig. 8c ), we conducted ChIP-seq on H3K27ac, a super-enhancer marker that reflects epigenetic status for T cell activation [25] [26] [27] . Notably, NR4A1 peaks overlapped sharply with H3K27ac sites in NR4A1-overexpressing T cells, and the dominant region of co-localization was the classical NR4A1-binding consensus sequence (Fig. 4c) . Further examination of H3K27ac distribution in the presence or absence of NR4A1 demonstrated that NR4A1 binding positively correlated with H3K27ac modifications in activated T cells at the super-enhancer region (Extended Data Fig. 8g) .
In a context of normal NF-AT signal transduction, insufficient AP-1 mediates T cell hyporesponsiveness 7, 28 . We reasoned that, given that Nr4a1 peaks co-localized with AP-1-binding sites, NR4A1 might regulate T cell tolerance by occupying these sites. Electrophoretic mobility shift assays (EMSAs) and a luciferase reporter assay demonstrated that NR4A1 specifically antagonized the AP-1-mediated transcriptional program (Extended Data Fig. 9a, b) . Moreover, inspection of genomewide NR4A1 and c-Jun distribution revealed that enforced NR4A1 expression suppressed the enrichment of c-Jun at TSSs (Fig. 4d) . To corroborate this result, we conducted anti-c-Jun ChIP assays on activated wild-type and Nr4a1
−/− CD4 + T cells. NR4A1 deletion increased the recruitment of c-Jun to the Jund, Pgpep1 and Naf1 genes, but had no effect on c-Jun binding at the promoter region of the Il2 gene locus. This suggests that NR4A1 has an indirect role in regulating Il2 transcription via downregulation of HIVEP3 (Extended Data Fig. 9c-e, g ).
Next, we tested whether NR4A1-mediated antagonism of AP-1 and enhancement of H3K27ac were directly correlated with transcriptional alterations in T cells. Combinational analysis of ChIP-seq and transcriptome data revealed that among 1,701 genes that were directly bound and regulated by NR4A1, 80% of the 841 downregulated gene loci exhibited reduction of c-Jun binding, whereas 73% of the 860 upregulated gene loci were marked with enhanced H3K27ac signals (Fig. 4e, f , and Supplementary Tables 6 and 7). As shown in Fig. 4g , NR4A1 bound to the loci of repressed genes Jund and Naf1 and antagonized c-Jun recruitment, but the H3K27ac signal remained intact. In addition, NR4A1 was able to bind at induced gene loci including Gata3, Nr4a1, Nt5e, Bach2 and Samhd1 concomitantly with H3K27ac enhancement (Fig. 4h and Extended Data Fig. 9f ), suggesting that NR4A1 might coordinate the action of these inhibitors 22, 24, 29 and thereby enforce a repressive program in T tol cells. T cell exhaustion-related genes such as Pdcd1, Havcr2 and Lag3, the expression levels of which were not increased in NR4A1-overexpressing T cells, were also found to recruit NR4A1-indicative of poised chromatin status for potential transcriptional activities (Extended Data Fig. 9h) .
In summary, our validation and classification of NR4A1-regulated genes have identified an NR4A1-centred regulatory circuit that orchestrates the characteristics of T tol cells (Fig. 4i) . Our findings, together with recent observations on the upregulation of NR4A1 in dysfunctional T cells 20, 22 , indicate that this regulatory circuit may be a suitable target for future therapeutic intervention. 
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Genes that bind NR4A1 Genes that do not bind NR4A1 H3K27ac −/− OT-I cells were sorted and adoptively transferred into tumour-bearing mice intravenously. Tumour size was measured in two dimensions by caliper and was expressed as the product of two perpendicular diameters. Tumours were isolated and processed with a mouse tumour dissociation kit (Miltenyi; 130-096-730). Tumour-infiltrating T cells were collected using Percoll density centrifugation (40% versus 70%), and subjected to flow cytometry analysis. Specifically, for Fig. 3c, d and Extended Data Fig. 6a-c −/− OT-I cells (3 × 10 6 cells per mouse) were adoptively transferred into mice intravenously. Tumour sizes were monitored after adoptive transfer. To assess tumour-infiltrating donor T cells, mice were euthanized 6 days after T cell transfer. Donor-derived T cells were collected from tumour, draining lymph nodes and spleens, and subjected to flow cytometry analysis. For Extended Data Fig. 6d-i, CD45 .1 + B6SJL congenic mice were subcutaneously injected with E.G7 tumour cells (5 × 10 5 cells per mouse) in one flank. Seven days later, mice were adoptively transferred with wild-type or Nr4a1 −/− OT-I cells (2 × 10 5 cells per mouse) intravenously. Twentyfive days after adoptive transfer, mice were euthanized and tumour sizes were measured. Donor-derived T cells were collected from tumour, draining lymph nodes and spleens, and subjected to flow cytometry analysis. ATAC-seq, data analysis for open chromatin regions and RNA sequencing. A total of 1 × 10 6 E.G7 cells were injected subcutaneously into 6 to ~10-week-old female C57BL/6J mice (six mice per group). This was followed by intraperitoneal injection of control or anti-PD-1 antibody at a dosage of 75 μg per mouse every 3 days starting from day 9. On day 21, mice were euthanized and subcutaneous tumours were digested with 1 mg ml −1 collagenase D supplemented with 10 U ml −1 DNase I. OVA-specific CD8 + TILs were stained with H-2K b -SIINFEKL tetramer and sorted using a BD FACSAria cell sorter, and gene profiling, ATACseq library construction and high-throughput sequencing 30 were performed on approximately 15,000-50,000 sorted cells. ATAC-seq data for tumour-infiltrating OVA-specific CD8 + T cells isolated from E.G7 tumour cell-bearing mice treated with anti-PD-1 or control antibody are available at the Gene Expression Omnibus (GEO), with accession code GSE110251 30 . Paired-end reads were mapped to the mm10 reference genome using Bowtie2. Only concordantly mapped pairs were kept for further analysis. Peak calling was performed using MACS2 to identify areas of sequence tag enrichment. BedTools was used to find common intersections between identified peaks (1 base pair (bp) minimum overlap) and to create a merged peak list. DNA transcription factor motif analysis across the merged peak list was computed using hypergeometric optimization of motif enrichment (HOMER; homer.ucsd.edu/homer/). Fold enrichment over background was calculated by dividing the number of target sequences with motif (12, 391) by the number of background sequences with motif (37,059). Transcription factors with a fold enrichment over background that was larger than one were plotted.
RNA-sequencing data of tumour-infiltrating OVA-specific CD8 + T cells from E.G7 tumour cell-bearing-mice treated with anti-PD-1 or control antibody were obtained from GEO accession GSE110249 30 . Clean reads were mapped to the mm10 reference genome and the fragments per kilobase of exon per million fragments mapped (FPKM) was calculated using Bowtie2. NR4A1 expression was compared between OVA-specific CD8 + TILs from mice treated with anti-PD-1 and control antibody.
Colitis model. Rag1
−/− mice were injected intravenously with 4 × 10 5 syngeneic CD4
hi wild-type or Nr4a1 −/− T cells. Body weights were monitored daily. Mice with clinical signs of disease were euthanized so that the severity of colitis could be assessed. After removal of Peyer's patches, intestine and colon tissues were cut into pieces for haematoxylin and eosin (H&E) staining. After digestion with collagenase D, T cells from the lamina propria were isolated using Percoll density centrifugation and subjected to flow cytometry analysis. Immunization and flow cytometry. Mice (6-8 weeks old; 3-5 per group) were immunized with OT-II peptide or OVA (100 μg ml 
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hi T cells from OT-II or C57BL/6 mice were sorted using fluorescence-activated cell sorting (FACS) and activated with plate-bound anti-CD3e (clone 2C11, BD Biosciences) and anti-CD28 (clone 37.51, BD Biosciences) under neutral conditions. Thirty-six hours after activation, cells were infected with retrovirus RV-Nr4a1-GFP or control empty vector (RV-vector-GFP). Two days after infection, cells were sorted (using FACS) for adoptive transfer or were restimulated with pre-coated anti-CD3e. Cell transfer numbers were 1 × + T cells were restimulated with plate-coated anti-CD3 and fixed with 1% formaldehyde, followed by digestion with MNase cocktail (Active Motif). Chromatin from 4 × 10 6 cells was used for each ChIP experiment. Antibodies against H3K4me3 (ab8580; Abcam), H3K27me3 (07-449; Millipore), H3K27ac (ab4729; Abcam), NR4A1 (14-5964-82; clone 357, eBioscience), c-Jun (sc-45x; Santa Cruz) and haemagglutinin (3724, clone C29F4; Cell Signaling Technology) were used. Antibody-DNA complexes were captured by protein A magnetic beads (Invitrogen). The immunoprecipitated DNA was purified and subjected to PCR assessment or/and sequencing library preparation. All sequencing libraries were prepared using the TruSeq ChIP Sample Prep Kit (Illumina) according to the manufacturer's protocol. The DNA libraries of H3K4me3 and H3K27me3 for T tol cells were sequenced with the Illumina 1G Genome Analyzer at the Institute for Systems Biology, and the rest of the DNA libraries were sequenced with Illumina HiSeq 2500 at the BGI Genomics company. Sequence reads of 50 bp were obtained using the CASAVA v.1.8.2 package (Illumina). All reads were mapped to the mm9 mouse genome and uniquely mapped reads were processed further for peak identification. SICER v.1.1 8 was used to identify significant peaks (FDR of 5%) with input DNA (ChIP-seq) as the control. Outputs of the peak files were converted to browser-extensible data (BED) files and viewed with the University of California, Santa Cruz (UCSC) genome browser and the integrative genomics viewer (IGV; v.2.4.5). HOMER was used to perform the consensus binding motif analysis for NR4A1. To calculate the tag density of NR4A1 binding, the epigenetic modifications around TSSs, or the centres of NR4A1-binding sites, uniquely mapped tags were summarized in 20-bp windows and all window tag counts were normalized by the total number of bases in the windows and the total read number of the given sample. Co-localization of NR4A1-binding sites with AP-1 and H3K27ac consensus motifs was analysed with HOMER software, and the binding sites of NR4A1, H3K27ac and AP-1 were first defined using SICER v.1.1. A binding site was defined as one or several consecutive 200-bp windows of the genome in which there was a statistically significant enrichment of sequencing reads against the background. Any area where part of one transcription factor-binding site overlapped with another one was defined as the overlay of the two binding sites. Genomic coordinates of mouse CD4
+ T cell super-enhancers were calculated using the rank ordering of super-enhancers (ROSE) algorithm 25, 27 on H3K27ac signal intensity across the genome 26 . EMSA and luciferase reporter assays. Nuclear extracts were prepared from empty vector-or RV-Nr4a1-GFP-transduced CD4 + T cells with or without phorbol myristate acetate (PMA)/ionomycin stimulation. Nuclear extracts of 5 × 10 6 cells were prepared with a nuclear and cytoplasmic extraction kit (78833; ThermoFisher Scientific) and protein concentrations were determined with a bicinchoninic acid (BCA) protein assay kit (23225; ThermoFisher Scientific), using bovine serum albumin standards. For further quantification of c-Jun and c-Fos in nuclear extracts, western blotting assays were performed using anti-c-Fos (clone 9F6; Cell Signaling Technology) and anti-c-Jun (clone 60A8; Cell Signaling Technology) antibodies. EMSA analysis was performed with 5 μg of nuclear extracts and a biotin-labelled double-stranded AP-1 probe (5′-CGCTTGATGACTCAGCCGGAA-3′; Santa Cruz) and OCT-1 (5′-TGTCGAATGCAAATCACTAGAA-3′; Santa Cruz).
For the supershift assay, 0.5 μg of anti-c-Jun antibody (sc-45x; Santa Cruz) was pre-incubated with nuclear extract. EMSA samples were run on a 5% native polyacrylamide gel. The gels were blotted onto a positively charged nylon membrane, blocked, incubated with horseradish peroxidase (HRP)-conjugated avidin and developed using the chemiluminescent nucleic acid detection module kit (89880; ThermoFisher Scientific).
Jurkat cells were co-transfected with RV-Nr4a1-GFP or empty vector with AP-1 or NF-AT reporter constructs (firefly; Clontech) treated with PMA/ionomycin for 6 h. Renilla luciferase plasmid was used as a control. Cell samples were lysed and subjected to luciferase assessment (Promega). qRT-PCR analysis. Total RNA was extracted with Trizol reagent (Invitrogen). Oligo (dT) 18 Primer and M-MLV Reverse Transcriptase (Invitrogen) were used to generate cDNA. Gene expression was examined with the iQ SYBR real-time kit (Bio-Rad Laboratories). Data were normalized using beta-actin (Actb) as the reference gene. The primer pairs for qRT-PCR analysis of Il2, Ifng, Cblb and Tbx21 were previously described 18 . Primer pairs for detection of mouse Nr4a1, Itch, Klf4, Hivep3 and Lpin2 were as follows: Nr4a1, forward, 5′-AGTTGGGGGAGTGTGCTAGA-3′; reverse, 5′-GCTTGAATACAGGGCATCTCCAG-3′. Itch, forward, 5′-ACCCT AAAGTTGTGGGGATGG-3′; reverse, 5′-GTTTGGCTGAGATGACAGTGA-3′. Klf4, forward, 5′-GACTAACCGTTGGCGTGAGG-3′; reverse, 5′-GTCTAGGTCCAGGAGGTCGT-3′. Hivep3, forward, 5′-CCCCCTA GTTCTC TGCCTCT-3′; reverse, 5′-GCTTAGATCGCAGGAGGGAC-3′. Lpin2, forward, 5′-TGTTTGTGGTGCCTTCACCT-3′; reverse, 5′-TGGTTTGAGA CAGAATCCCAGG-3′. Statistics. Unless otherwise indicated, a Student's t-test or one-way ANOVA was used for two-group comparisons. P values of <0.05 were considered significant. Statistical analysis was performed with Graphpad Prism 7. No statistical methods were used to predetermine sample size. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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